Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates

Pyrazinamide (PZA) is one of the first-line agents used for the treatment of tuberculosis. However, current phenotypic PZA susceptibility testing in the Bactec MGIT 960 system is unreliable, and false resistance is well documented. Rapid identification of resistance-associated mutations can confirm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Mok, Simone, Roycroft, Emma, Flanagan, Peter R., Montgomery, Lorraine, Borroni, Emanuele, Rogers, Thomas R., Fitzgibbon, Margaret M.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2021
Matèries:
Susceptibility
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284449/
https://ncbi.nlm.nih.gov/pubmed/33972244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02617-20
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars